Creso Pharma Limited (COPHF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
COPHF steht fuer Creso Pharma Limited, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 56/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Creso Pharma Limited (COPHF) Gesundheitswesen & Pipeline-Uebersicht
Creso Pharma Limited focuses on developing and commercializing cannabis and hemp-based products for both human and animal health, operating in a global market with a diverse product portfolio including nutraceuticals and therapeutic treatments, but faces challenges related to profitability and market competition.
Investmentthese
Creso Pharma Limited presents a speculative investment opportunity within the rapidly evolving cannabis and hemp-based health and wellness market. The company's diverse product portfolio targeting both human and animal health provides multiple revenue streams. However, the company's negative profit margin of -377.3% raises concerns about its financial sustainability. Investors should closely monitor Creso Pharma's ability to improve its profitability and achieve sustainable growth. Key catalysts include successful product launches and expansion into new geographic markets. The high beta of -24.81 indicates extreme volatility compared to the market, suggesting a high-risk investment profile. The company's ability to navigate regulatory hurdles and maintain a competitive edge will be crucial for its long-term success.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.13 billion indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -0.40 reflects the company's current lack of profitability.
- Profit margin of -377.3% highlights significant challenges in achieving profitability.
- Gross margin of 3.3% suggests limited ability to generate profit from sales after accounting for the cost of goods sold.
- Beta of -24.81 indicates extreme volatility compared to the market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diverse product portfolio targeting both human and animal health.
- Presence in multiple geographic regions.
- Focus on pharmaceutical-grade cannabis and hemp-based products.
- Established cultivation and processing capabilities.
Schwaechen
- Negative profit margin and limited profitability.
- High beta indicating significant market volatility.
- Reliance on evolving regulatory landscape.
- Limited brand recognition compared to larger competitors.
Katalysatoren
- Upcoming: Potential regulatory approvals for new cannabis and hemp-based products in key markets.
- Ongoing: Expansion of distribution network through strategic partnerships.
- Ongoing: Increasing consumer acceptance of cannabis and hemp-based health and wellness products.
- Upcoming: Launch of new innovative products targeting specific therapeutic areas.
- Ongoing: Growing demand for animal health products containing cannabis and hemp.
Risiken
- Potential: Changes in regulatory landscape and stricter regulations on cannabis and hemp products.
- Ongoing: Intense competition from established pharmaceutical companies and other cannabis producers.
- Potential: Fluctuations in cannabis and hemp prices affecting profitability.
- Potential: Negative public perception of cannabis products impacting demand.
- Ongoing: Limited financial resources and potential need for additional funding.
Wachstumschancen
- Expansion into New Geographic Markets: Creso Pharma can drive growth by expanding its presence in key markets such as North America and Europe. The increasing legalization of cannabis and hemp-based products in these regions presents significant opportunities for market penetration. Strategic partnerships with local distributors and retailers can facilitate market entry and accelerate revenue growth. The global cannabis market is projected to reach $47 billion by 2027, providing a substantial addressable market for Creso Pharma.
- Development of Innovative Products: Investing in research and development to create innovative cannabis and hemp-based products can drive growth and differentiate Creso Pharma from its competitors. Focusing on specific therapeutic areas, such as pain management and mental health, can attract a loyal customer base and generate recurring revenue. The nutraceutical market is expected to grow to $400 billion by 2030, offering a significant opportunity for Creso Pharma to expand its product portfolio.
- Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships with other companies in the cannabis and hemp industry can accelerate growth and expand Creso Pharma's market reach. Acquiring companies with complementary product portfolios or established distribution networks can create synergies and enhance the company's competitive position. The cannabis industry is consolidating, with larger companies acquiring smaller players to gain market share and expand their operations.
- Focus on Animal Health Products: The animal health market presents a significant growth opportunity for Creso Pharma, particularly with its anibidiol product. As pet owners increasingly seek natural and alternative treatments for their animals, the demand for cannabis and hemp-based products for pets is expected to grow. Expanding the anibidiol product line and developing new animal health products can drive revenue growth and establish Creso Pharma as a leader in this niche market. The global animal health market is projected to reach $70 billion by 2027.
- Enhancing E-commerce Capabilities: Investing in e-commerce capabilities and online marketing can drive direct-to-consumer sales and expand Creso Pharma's customer base. Developing a user-friendly online platform and implementing targeted marketing campaigns can attract new customers and increase brand awareness. The e-commerce market is growing rapidly, with consumers increasingly purchasing health and wellness products online. Strengthening its online presence can enable Creso Pharma to reach a wider audience and generate higher sales.
Chancen
- Expansion into new geographic markets.
- Development of innovative cannabis and hemp-based products.
- Strategic acquisitions and partnerships.
- Growth in the animal health market.
Risiken
- Intense competition from established pharmaceutical companies and other cannabis producers.
- Changing regulatory landscape and potential for stricter regulations.
- Fluctuations in cannabis and hemp prices.
- Potential for negative public perception of cannabis products.
Wettbewerbsvorteile
- Proprietary formulations and intellectual property related to cannabis and hemp-based products.
- Established presence in multiple geographic regions, including Europe, the Middle East, North America, and Asia Pacific.
- Focus on pharmaceutical-grade products, ensuring high quality and safety standards.
- Diverse product portfolio targeting both human and animal health.
Ueber COPHF
Creso Pharma Limited, established in 2015 and headquartered in Nedlands, Australia, is a healthcare company specializing in the development, registration, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products. The company's mission is to provide innovative and effective treatments for both human and animal health. Creso Pharma operates across several key regions, including Europe, the Middle East, North America, and the Asia Pacific, reflecting its global ambitions and market reach. The company's product portfolio includes a range of therapeutic and nutraceutical products. Key offerings include anibidiol, a complementary feed product designed for companion animals to support their well-being. CannaQIX is another prominent product, a nutraceutical containing hemp oil extract, vitamins, and zinc, aimed at reducing stress and supporting psychological and nervous functions. Additionally, Creso Pharma develops and markets topical and skin care products, such as cannaDOL, a CBD-based topical gel formulated with cooling and warming essential oils. Creso Pharma's business activities encompass the entire value chain, from cultivation and processing of cannabis to the manufacturing and distribution of finished products. The company cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products, ensuring a consistent supply and quality control. Creso Pharma aims to establish itself as a leader in the cannabis and hemp-based health and wellness sector through continuous innovation, strategic partnerships, and expansion into new markets.
Was das Unternehmen tut
- Develops pharmaceutical-grade cannabis products.
- Registers and commercializes cannabis and hemp-based nutraceuticals.
- Creates treatments for human health using cannabis and hemp.
- Develops treatments for animal health using cannabis and hemp.
- Cultivates and processes cannabis products.
- Supplies cannabis retail products.
- Markets topical and skin care products containing CBD.
Geschaeftsmodell
- Develops and sells cannabis and hemp-based products for human and animal health.
- Generates revenue through the sale of nutraceuticals and therapeutic products.
- Cultivates and processes cannabis to ensure product quality and supply.
- Distributes products through retail channels and online platforms.
Branchenkontext
Creso Pharma Limited operates within the rapidly expanding cannabis and hemp-based health and wellness industry. This sector is characterized by increasing consumer acceptance, evolving regulatory landscapes, and growing demand for alternative health solutions. The market is highly competitive, with numerous companies vying for market share. Creso Pharma's focus on pharmaceutical-grade products and its presence in multiple geographic regions position it to capitalize on the industry's growth. However, the company faces competition from established pharmaceutical companies and other cannabis producers. The global cannabis market is projected to reach billions of dollars in the coming years, presenting significant opportunities for companies like Creso Pharma.
Wichtige Kunden
- Individuals seeking alternative health and wellness solutions.
- Pet owners looking for natural treatments for their animals.
- Retailers and distributors of health and wellness products.
- Pharmacies and healthcare providers.
Finanzdaten
Chart & Info
Creso Pharma Limited (COPHF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer COPHF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer COPHF.
Kursziele
Wall-Street-Kurszielanalyse fuer COPHF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von COPHF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: William Lay
CEO
William Lay serves as the CEO of Creso Pharma Limited. His background includes extensive experience in the pharmaceutical and healthcare industries, with a focus on strategic leadership and business development. He has held various leadership positions in both public and private companies, contributing to his expertise in navigating complex regulatory environments and driving growth. His experience encompasses product development, commercialization, and market expansion strategies.
Erfolgsbilanz: Under William Lay's leadership, Creso Pharma has focused on expanding its product portfolio and geographic reach. Key achievements include the launch of new cannabis and hemp-based products and the establishment of strategic partnerships to enhance distribution capabilities. He has also overseen efforts to improve operational efficiency and strengthen the company's financial position. His strategic decisions have been instrumental in positioning Creso Pharma for long-term growth in the evolving cannabis market.
COPHF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Creso Pharma Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and greater price volatility.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher price volatility compared to stocks listed on major exchanges.
- Risk of delisting or suspension from the OTC market.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor the company's news and press releases for any material developments.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory actions or legal disputes.
- Company has been in operation since 2015.
- Presence in multiple geographic regions.
- Focus on pharmaceutical-grade products.
- Development of products for both human and animal health.
Haeufige Fragen zu COPHF
What are the key factors to evaluate for COPHF?
Creso Pharma Limited (COPHF) currently holds an AI score of 56/100, indicating moderate score. Key strength: Diverse product portfolio targeting both human and animal health.. Primary risk to monitor: Potential: Changes in regulatory landscape and stricter regulations on cannabis and hemp products.. This is not financial advice.
How frequently does COPHF data refresh on this page?
COPHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven COPHF's recent stock price performance?
Recent price movement in Creso Pharma Limited (COPHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio targeting both human and animal health.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider COPHF overvalued or undervalued right now?
Determining whether Creso Pharma Limited (COPHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying COPHF?
Before investing in Creso Pharma Limited (COPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding COPHF to a portfolio?
Potential reasons to consider Creso Pharma Limited (COPHF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diverse product portfolio targeting both human and animal health.. Additionally: Presence in multiple geographic regions.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of COPHF?
Yes, most major brokerages offer fractional shares of Creso Pharma Limited (COPHF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track COPHF's earnings and financial reports?
Creso Pharma Limited (COPHF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for COPHF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than data for exchange-listed companies.
- Analyst sentiment is based on limited coverage and may not be representative of the broader market.